Federal Concerns Regarding Sanofi's 340B Credit Proposal
The Health Resources and Services Administration (HRSA) has raised alarms regarding Sanofi SA's proposed credit model related to certain outpatient drugs under the 340B program. This initiative, scheduled to commence on January 6, 2025, has been criticized for purportedly violating Sanofi's responsibilities under the 340B statute.
The Proposed Credit Model
Sanofi's plan involves a credit system for covered outpatient drugs aimed at specific covered entities such as hospitals that provide critical care. The proposed model states that these entities would initially pay the Wholesale Acquisition Cost (WAC) and later submit their purchase data to obtain a credit reflecting the difference between the WAC and the 340B price.
Details of the Implementation
According to the announcement made on November 22, 2024, this new credit model will expand to include consolidated health centers starting March 1, 2025, which marks an important step in the company's approach to outpatient drug pricing.
HRSA's Legal Statement
HRSA has emphasized that the 340B statute clearly defines the ceiling price that covered entities should expect to pay for outpatient drugs. Any pharmaceutical manufacturer must adhere strictly to this pricing structure without imposing additional conditions. Sanofi's approach, which appears to require payment above this ceiling price without obtaining necessary approvals, raises significant legal concerns.
Consequences of Non-Compliance
The agency has warned that if Sanofi proceeds with its credit proposal, it could face serious legal repercussions. These might include termination of Sanofi’s Pharmaceutical Pricing Agreement (PPA) along with civil monetary penalties for non-compliance with the pricing regulations.
Industry Reactions and Legal Battles
In a parallel situation, Bristol-Myers Squibb Co has taken legal action against HRSA and the U.S. Department of Health and Human Services. The lawsuit challenges the agency's rejection of its proposed rebate model for the 340B Drug Pricing Program, asserting that these actions violate federal law.
Market Response
As news broke regarding HRSA’s warning, the financial markets reacted. Sanofi's stock, identified under the ticker SNY, saw a rise of 4.14%, trading at $47.79 in the premarket session, indicating investor confidence despite the ongoing scrutiny.
Future Compliance and Obligations
HRSA's instruction for Sanofi to halt the proposed credit model underscores the importance of compliance for pharmaceutical companies. By December 20, 2024, Sanofi must confirm that it will cease implementation, highlighting the ongoing tension between pharmaceutical companies and regulatory agencies.
Frequently Asked Questions
What is Sanofi's 340B credit model?
The 340B credit model proposed by Sanofi involves allowing certain healthcare entities to pay the Wholesale Acquisition Cost and claim credits based on the 340B price difference.
Why has HRSA warned Sanofi?
HRSA has warned Sanofi that its credit model may violate legal obligations under the 340B statute, which requires pharmaceuticals to charge covered entities no more than the ceiling price.
What could be the consequences for Sanofi?
Potential consequences for Sanofi include civil monetary penalties and the termination of its Pharmaceutical Pricing Agreement if it proceeds with the credit model.
How does this impact the 340B program?
The controversy surrounding Sanofi's credit model highlights ongoing challenges and legal interpretations concerning drug pricing within the 340B program, affecting access and affordability for covered entities.
What action is required from Sanofi?
HRSA has instructed Sanofi to halt its proposed credit model implementation and to confirm compliance by December 20, 2024, to avoid legal penalties.
